Bausch Health Companies Inc. BHC
We take great care to ensure that the data presented and summarized in this overview for Bausch Health Companies Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BHC
View all-
Icahn Carl C Sunny Isles Beach, FL34.7MShares$243 Million2.99% of portfolio
-
Goldentree Asset Management LP New York, NY34.3MShares$240 Million23.91% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny32.8MShares$230 Million11.35% of portfolio
-
Nomura Holdings Inc Tokyo, M021.5MShares$150 Million0.31% of portfolio
-
Healthcare Of Ontario Pension Plan Trust Fund Toronto, A613MShares$91 Million0.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$82.4 Million0.0% of portfolio
-
Royal Bank Of Canada Toronto, A69.35MShares$65.4 Million0.01% of portfolio
-
Maple Rock Capital Partners Inc. Toronto, A67.81MShares$54.7 Million2.73% of portfolio
-
National Bank Of Canada7.74MShares$54.2 Million0.06% of portfolio
-
Sg Americas Securities, LLC6.15MShares$43.1 Million0.17% of portfolio
Latest Institutional Activity in BHC
Top Purchases
Top Sells
About BHC
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Insider Transactions at BHC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 21
2025
|
Frank D. Lee Director |
SELL
Open market or private sale
|
Direct |
15,912
-17.74%
|
$111,384
$7.66 P/Share
|
Aug 14
2025
|
John Paulson |
BUY
Open market or private purchase
|
Indirect |
34,721,118
+32.92%
|
$312,490,062
$9.0 P/Share
|
Aug 13
2025
|
John Paulson |
BUY
Open market or private purchase
|
Indirect |
86,409
+0.24%
|
$604,863
$7.06 P/Share
|
Aug 12
2025
|
John Paulson |
BUY
Open market or private purchase
|
Indirect |
1,156,640
+3.12%
|
$6,939,840
$6.88 P/Share
|
Aug 11
2025
|
John Paulson |
BUY
Open market or private purchase
|
Indirect |
2,000,000
+5.44%
|
$12,000,000
$6.35 P/Share
|
Jul 25
2025
|
Michael Goettler Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,149
+50.0%
|
-
|
Jul 25
2025
|
Sandra Leung Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,149
+50.0%
|
-
|
Jul 17
2025
|
Aimee J. Lenar EVP, US Pharma |
BUY
Grant, award, or other acquisition
|
Direct |
30,847
+10.58%
|
-
|
Jul 15
2025
|
Aimee J. Lenar EVP, US Pharma |
SELL
Payment of exercise price or tax liability
|
Direct |
22,736
-9.0%
|
$136,416
$6.42 P/Share
|
Jul 14
2025
|
Steven Hyosig Lee SVP, Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
27,371
+50.0%
|
-
|
Jun 30
2025
|
John Paulson |
BUY
Grant, award, or other acquisition
|
Direct |
9,384
+2.67%
|
-
|
Jun 30
2025
|
Brett Icahn Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,034
+1.8%
|
-
|
Jun 30
2025
|
Amy B Wechsler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,032
+0.39%
|
-
|
Jun 13
2025
|
John Paulson |
BUY
Open market or private purchase
|
Indirect |
3,564,059
+9.8%
|
$17,820,295
$5.94 P/Share
|
Jun 12
2025
|
John Paulson |
BUY
Open market or private purchase
|
Indirect |
1,005,376
+3.33%
|
$5,026,880
$5.47 P/Share
|
Jun 11
2025
|
John Paulson |
BUY
Open market or private purchase
|
Indirect |
1,029,098
+3.52%
|
$5,145,490
$5.24 P/Share
|
Jun 10
2025
|
John Paulson |
BUY
Open market or private purchase
|
Indirect |
754,134
+2.7%
|
$3,770,670
$5.05 P/Share
|
May 16
2025
|
Christian A Garcia Director |
BUY
Grant, award, or other acquisition
|
Direct |
54,347
+37.73%
|
-
|
May 16
2025
|
Frank D. Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
54,347
+37.73%
|
-
|
May 16
2025
|
Sarah B Kavanagh Director |
BUY
Grant, award, or other acquisition
|
Direct |
54,347
+18.69%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.85M shares |
---|---|
Open market or private purchase | 44.3M shares |
Payment of exercise price or tax liability | 359K shares |
---|---|
Open market or private sale | 29.7K shares |